Early Start Of Tenofovir Treatment Achieves Better Viral Suppression In Pregnant Women With A High HBV Viral Load: A Real-World Prospective Study

References

• Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med. 2018;378(10):911–923. doi:10.1056/NEJMoa170813129514030
   PubMed Web of Science ®Google Scholar
• Cressey TR, Harrison L, Achalapong J, et al. Tenofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis B virus. Antimicrob Agents Chemother. 2018;62(12). doi:10.1128/AAC.01686-18
   Web of Science ®Google Scholar
• Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int. 2009;29:133–139.
   PubMed Web of Science ®Google Scholar
• Song J, Yang F, Wang S, et al. Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: A meta-analysis. J Viral Hepat. 2019;26(3):397–406.30417469
   PubMed Web of Science ®Google Scholar
• Jourdain G, Ngo-Giang-Huong N, Cressey TR, et al. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis. 2016;16:393.27506549
   PubMed Web of Science ®Google Scholar
• Brown RS, McMahon BJ, Lok ASF, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63(1):319–333.26565396
   PubMed Web of Science ®Google Scholar
• Dionne-Odom J, Tita AT, Silverman NS; Society for Maternal-Fetal M. #38: hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016;214(1):6–14.26454123
   PubMed Web of Science ®Google Scholar
• Beasley RP. Hepatitis-B virus - the major etiology of hepatocellular-carcinoma. Cancer. 1988;61(10):1942–1956.2834034
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.14996343
   PubMed Web of Science ®Google Scholar
• Wang M, Bian Q, Zhu Y, et al. Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther. 2019;49(2):211–217. doi:10.1111/apt.1506430506691
   PubMed Web of Science ®Google Scholar
• Hyun MH, Lee YS, Kim JH, et al. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther. 2017;45(12):1493–1505. doi:10.1111/apt.1406828436552
   PubMed Web of Science ®Google Scholar
• Cui F, Woodring J, Chan P, Xu F. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. Int J Epidemiol. 2018;47(5):1529–1537. doi:10.1093/ije/dyy07729757383
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Buti M, Cornberg M, et al. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–185.22436845
   PubMed Web of Science ®Google Scholar
• Rapicetta M. New perspectives and models for hepatitis B vaccines and immunization. Vaccine. 2008;27(25):3271–3275. doi:10.1016/j.vaccine.2009.01.063
   Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–2455. doi:10.1056/NEJMoa080287819052126
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.29405329
   PubMed Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283. doi:10.1002/hep.2815626566064
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization; 2015.
   Google Scholar
• Korean Association for the Study of the L. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2016;22(1):18–75. doi:10.3350/cmh.2016.22.1.1827044762
   PubMedGoogle Scholar
• Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–386. doi:10.1002/hep.2783725851052
   PubMed Web of Science ®Google Scholar
• Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–2334. doi:10.1056/NEJMoa150866027305192
   PubMed Web of Science ®Google Scholar
• Brown RS Jr., McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63(1):319–333. doi:10.1002/hep.2830226565396
   PubMed Web of Science ®Google Scholar
• Fan R, Yin XR, Hou JL. Prevention of peripartum hepatitis B transmission. N Engl J Med. 2016;375(15):1496–1498. doi:10.1056/NEJMc1609991
   Google Scholar
• Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61(3):502–507.24801414
   PubMed Web of Science ®Google Scholar
• Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014. doi:10.1002/hep.27034
   Web of Science ®Google Scholar
• Yi W, Pan CQ, Li MH, et al. The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B. Am J Gastroenterol. 2018;113(5):686–693. doi:10.1038/s41395-018-0010-229487412
   PubMed Web of Science ®Google Scholar
• Kochaksaraei GS, Castillo E, Osman M, et al. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat. 2016;23(1):15–22. doi:10.1111/jvh.2015.23.issue-126192022
   PubMed Web of Science ®Google Scholar
• Nguyen V, Tan PK, Greenup AJ, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther. 2014;39(10):1225–1234. doi:10.1111/apt.1272624666381
   PubMed Web of Science ®Google Scholar
• Wang J, Liu J, Qi C, et al. Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV. Antivir Ther. 2015;20(7):681–687. doi:10.3851/IMP298126215771
   PubMed Web of Science ®Google Scholar